



Canadian
Cancer Clinical
Trials Network

Canadian Cancer Clinical Trials Network

3CTN Y6 Performance Report

April 1, 2019 – March 31, 2020


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials.....	2
Patient Recruitment at All Network Sites.....	2
Portfolio Trials and Accruals by Region/Site.....	3
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba	3
Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba	4
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario	5
Number of active recruiting 3CTN Portfolio trials – Ontario	6
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec	7
Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec	8
Section B: 3CTN Portfolio Metrics	9
Active Recruiting Portfolio Trials by Disease Site and Phase.....	9
Portfolio Impact Assessment.....	10
Overview of Portfolio Applications – Process Efficiency	11
Site Efficiency Metrics	12
Appendix: Additional Notes	13
Table 1: Site Efficiency Metrics Definitions	13
Table 2: Study Impact Criteria Definitions.....	14
Table 3. Reporting Periods and Dates Q4 2014/15 – Q4 2019/20.....	15

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



Notes:

- 1777 patients were recruited to Portfolio trials in Quarter 4. Y6 target is to achieve 60% above pre-3CTN baseline.
- Y6's total accrual of 5686 patients exceeded the Year 6 target of 3966 patients for the Network overall.
- The TMIST trial being conducted by 3 Ontario cancer centres and 2 Quebec cancer centres contributed 2294 (40.3%) patients to the Network total recruitment during Y6.
- Overall, ~48% of Adult Sites (20 out of 42) have exceeded their Y6 target of 160% to baseline.
- *Pediatric centres don't have a recruitment target, therefore the graph shows Pediatric progress to pre-3CTN baseline recruitment. 1 Pediatric site exceeded their pre-3CTN baseline.

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 (2019-20)						
						Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target*
CancerCare Manitoba	99	72	102	90	98	16	18	11	6	51	52%	32%
Prairie Mountain Health	1	0	0	0	1	0	0	1	0	1	100%	63%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	0	1	1	5	7	39%	-
Manitoba Total	118	92	116	107	103	16	19	13	11	59	50%	33%
BC Cancer Agency - Vancouver Centre	106	117	152	127	107	29	22	34	25	110	104%	65%
Abbotsford Centre	16	28	14	22	22	0	1	0	0	1	6%	4%
Centre for the North, Prince George	1	6	4	8	9	5	4	1	0	10	1000%	625%
Sindi Ahluwalia Hawkins Centre for the Southern Interior	38	40	30	28	38	10	7	3	13	33	87%	54%
Vancouver Island Centre	26	44	69	64	69	18	11	33	16	78	300%	188%
British Columbia Total	187	235	269	249	245	62	45	71	54	232	124%	78%
Alberta Health Services, Cross Cancer Institute	102	112	137	99	103	90	101	19	100	310	304%	190%
Alberta Health Services, Tom Baker Cancer Centre	76	140	125	154	139	100	131	6	104	341	449%	280%
Alberta Total	178	252	262	253	242	190	232	25	204	651	366%	229%
Western Region Total	483	579	647	609	590	268	296	109	269	942	195%	126%

* Pediatric sites don't have recruitment targets and are excluded in province and regional "% to Y6 Target" calculations

Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CancerCare Manitoba	37	28	27	29	23	22	19	16	22
Prairie Mountain Health	0	0	0	1	1	1	1	1	1
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10	9	8	9
BC Cancer Agency - Vancouver Centre	50	25	25	27	27	26	25	23	27
Abbotsford Centre	6	4	4	4	4	5	5	0	0
Centre for the North, Prince George	2	3	3	3	3	2	2	3	3
Sindi Ahluwalia Hawkins Centre for the Southern Interior	23	9	10	6	6	5	5	5	7
Vancouver Island Centre	12	5	6	5	5	8	7	6	6
Alberta Health Services, Cross Cancer Institute	29	29	28	30	29	27	26	27	21
Alberta Health Services, Tom Baker Cancer Centre	20	29	32	32	30	30	34	33	33

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 (2019-20)						
						Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target
London Health Sciences Centre	186	172	187	169	248	138	214	314	276	942	506%	317%
Grand River Regional Cancer Centre	20	13	43	32	34	2	5	7	5	19	95%	59%
Windsor Regional Cancer Centre	14	17	63	32	16	0	3	0	0	3	21%	13%
Hamilton Health Sciences, Juravinski Cancer Centre	181	231	247	454	345	65	40	59	53	217	120%	75%
Cambridge Memorial Hospital	11	2	5	4	5	1	3	4	0	8	73%	45%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	9	3	5	3	20	95%	60%
Walker Family Cancer Centre, Niagara Health System	17	22	13	23	37	17	5	11	7	40	235%	147%
Sunnybrook Health Sciences Centre, Sunnybrook Research Institute	141	229	398	363	651	155	163	164	156	638	452%	283%
Humber River Hospital	1	2	1	9	7	0	0	0	3	3	300%	188%
Michael Garron Hospital (Toronto East General Hospital)	2	2	1	7	2	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	384	533	473	720	121	128	146	148	543	137%	86%
Markham Stouffville Hospital	1	0	28	9	2	2	0	1	3	6	600%	375%
Mount Sinai Hospital	21	12	40	7	12	2	2	3	0	7	33%	21%
Northeast Cancer Centre - Health Sciences North	24	17	12	9	18	5	3	6	3	17	71%	44%
North York General Hospital	1	4	8	11	9	0	1	5	1	7	700%	438%
Royal Victoria Regional Health Centre	8	18	58	23	9	1	5	9	10	25	313%	195%
Southlake Regional Health Centre	10	15	75	26	68	8	10	6	8	32	320%	200%
St. Michael's Hospital	19	0	27	2	1	0	1	0	2	3	16%	10%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	2	1	0	1	4	15%	10%
Trillium Health Partners	27	5	51	10	12	2	3	2	3	10	37%	23%
William Osler Health System	1	0	29	13	0	1	5	4	6	16	1600%	1000%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	216	175	224	189	804	609%	381%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	23	16	24	26	89	217%	136%
Lakeridge Health, RSM Durham Regional Cancer Centre	22	26	70	18	15	8	7	16	5	36	164%	102%
Central Region Total	1323	1500	2507	2368	3198	778	793	1010	908	3489	264%	165%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
London Health Sciences Centre	79	45	46	46	40	47	52	54	57
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	8	8
Windsor Regional Cancer Centre	4	4	4	5	5	4	4	4	3
Hamilton Health Sciences, Juravinski Cancer Centre	51	29	27	30	32	22	26	24	34
Cambridge Memorial Hospital	5	2	2	3	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1	1	1	1
Walker Family Cancer Centre, Niagara Health System	10	8	7	8	7	6	6	8	7
Sunnybrook Health Sciences Centre, Sunnybrook Research Institute	10	32	34	34	35	34	36	36	35
Humber River Hospital	0	3	3	2	2	2	2	3	2
Michael Garron Hospital (Toronto East General Hospital)	3	2	2	2	2	1	1	1	1
Princess Margaret Cancer Centre	91	71	74	81	86	78	88	89	80
Markham Stouffville Hospital	0	0	0	1	1	1	0	1	1
Mount Sinai Hospital	6	4	4	4	4	4	5	6	3
Northeast Cancer Centre - Health Sciences North	10	6	7	7	8	7	7	7	7
North York General Hospital	0	3	4	3	3	3	5	4	1
Royal Victoria Regional Health Centre	5	8	6	6	6	6	6	9	10
Southlake Regional Health Centre	3	9	10	10	10	9	8	8	7
St. Michael's Hospital	4	1	1	1	2	2	2	3	2
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5	5	4	3
Trillium Health Partners	9	3	3	3	4	4	4	3	6
William Osler Health System	0	1	1	2	2	1	2	2	2
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41	36	34	15
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21	33	33	22
Lakeridge Health, RSM Durham Regional Cancer Centre	13	3	4	3	3	3	3	2	2

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 (2019-20)						
						Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target*
Nova Scotia Health Authority	39	40	52	45	42	7	4	5	4	20	51%	32%
Eastern Regional Health Authority	15	4	12	8	15	3	7	1	5	16	107%	67%
Janeway Child Health Centre	4	3	4	4	0	0	0	0	0	0	0%	-
Atlantic Total	58	47	68	57	57	10	11	6	9	36	62%	42%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	76	161	149	71	49	41	38	27	155	178%	111%
CISSS de l'Outaouais	3	0	4	32	1	0	4	0	1	5	167%	104%
CHU de Québec – Université Laval, adults	180	25	144	236	99	43	105	78	83	309	172%	107%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	18	14	17	12	61	133%	83%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	20	11	15	20	66	43%	27%
CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)	3	0	4	16	8	2	14	93	430	539	17967%	11229%
CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM)	60	12	51	49	23	7	4	2	2	15	25%	16%
CHU de Quebec - Pediatrics	17	14	7	17	22	5	5	6	5	21	124%	-
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	14	9	7	8	38	90%	-
Montreal Children's Hospital	24	23	14	20	8	2	3	2	3	10	42%	-
Quebec Total	615	251	622	763	400	160	210	258	591	1219	198%	135%
Eastern Region Total	673	298	690	820	457	170	221	264	600	1255	186%	126%

* Pediatric sites don't have recruitment targets and are excluded in province and regional "% to Y6 Target" calculations.


Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Eastern Regional Health Authority	6	4	6	5	6	8	9	10	9
Janeway Child Health Centre	5	11	9	9	9	5	9	6	6
CISSS de l'Outaouais	1	1	1	1	2	2	2	2	2
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	N/A	N/A	N/A	N/A	18	15	24	17
CHU de Québec – Université Laval, adults	39	19	20	26	26	26	26	25	30
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	14	15	17	17
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33	30	33	30
CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)	4	2	2	2	2	2	3	3	2
CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM)	6	12	13	11	10	10	8	11	10
CHU de Quebec - Pediatrics	11	13	16	17	15	17	15	13	11
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17	18	18	17
Montreal Children's Hospital	5	25	25	20	21	12	16	16	13

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Portfolio Impact Assessment

Objective: To provide a more specific and translatable impact description of 3CTN Portfolio trials for existing and future stakeholders.

Trial Categories of Interest	Breakthrough trial	Platform trial	Enhancement/derivative trial	Cross cancer trial	Sustaining trial	N/A	Total # of Trials per Study Criteria
Novel therapy	8	10	3	1			21
Rare cancer setting	2	26	9	1	8	1	46
Vulnerable populations		16	5	1	7		28
Precision medicine	6	37	12	4	5	2	62
Patient management		41	5	6	23	4	73
Lifestyle Interventions		7		1			8
N/A		7	1				8
Total # of Trials per Study Criteria	8	98	15	11	29	4	155

Note: A trial may fit into more than one categories; N=152 is the unique count of reviewed trials that are currently recruiting.

To see the Impact Analysis of the Portfolio click [here](#).

Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	87	24	8
2016	70	24	6
2017	44	19	5
2018	43	20	5
2019	47	38	1
2020	16	12	0

Facilitated Peer Review (FPR) Process²

Calendar Year	# Applications Completed	Average FPR Time (days)	Median FPR Time (days)
2015	5	47	33
2016	11	93	60
2017	2	53	53
2018	11	89	81
2019	14	97	83
2020	2	95	95

1. From application received to approve/decline the application for period, Jan 13, 2015 to July 7, 2020.
2. From start of peer review to date (i.e. site agreed to pursue peer review) to last reviewer submitted completed peer review package to 3CTN (approved trials only).

Additional link to interactive Portfolio Application report:

[Portfolio Applications Report](#)

3CTN Performance Report

Recruitment database lock & Portfolio snapshot date: July 7, 2020

Site Efficiency Metrics

Objective: To improve trial initiation time and forecasting of recruitment targets.

Province/ Population	Reporting Groups	Activation Timeline		Local Site REB Processing Time		Local Site REB Approval to First Patient Recruited		Site Open to Accrual to First Patient Recruited		Recruiting Period (from Trial Open - Closed to Accrual)		Site Accrual vs. Target	
		Average	Median	Average	Median	Average	Median	Average	Median	Average	Median	Average	Median
Alberta*	2	NA	NA	93	64	238	165	151	94	704	627	78%	60%
BC	5	238	190	87	62	226	162	79	37	710	705	102%	83%
Manitoba	2	208	184	67	55	284	226	128	85	891	733	75%	58%
Newfoundland	1	262	274	88	59	152	145	100	71	531	430	62%	33%
Nova Scotia	1	271	248	57	56	237	194	143	98	756	714	118%	100%
Ontario	24	222	172	28	6	211	156	114	59	595	479	86%	65%
Quebec	7	249	222	75	57	222	143	151	67	608	547	150%	60%
Pediatrics	5	203	141	79	49	388	187	326	124	770	606	69%	0%
Overall	47	229	181	53	28	230	162	133	61	647	540	95%	63%

*Trial activation timeline days not available

Notes:

- Data was taken for trials site open on or after Jan 1st 2014; definitions see Appendix
- Data that was negative or missing was excluded; projects in set up greater than or equal to 2014 included
- Accrual targets only counted for closed, terminated, archived and completed trials
- Data sourced from currently active 3CTN member sites only; Data still includes outliers, median is used to help reflect a more accurate central data trend

Additional links to interactive Site Efficiency Report:

[Site Efficiency Report](#)

Appendix: Additional Notes

Table 1: Site Efficiency Metrics Definitions

Metric	Definition/formula	2018-2022 Target	Source	Frequency Reported
Start date of site activation process to Site Open to Accrual (New for 2018-2022)	=site open to accrual – start date of site activation process Note: Start Date of Site Activation Process/Date Site Confirmed Participation= the date that the site has the critical decision and package to start the trial activation process (whichever date is later): 1) access to the protocol; 2) the site PIs has expressed interest in the trial; 3) the site has confirmed its participation as a site through a formal or informal review process	300 days (average)	Site	Quarterly
Centralized Site REB Processing Time (Lead applicant submission to approval)	=Centralized site REB approval date - Centralized site submission date	90 days (average)	Site/ethics board	Semi-annual
Local Site REB Processing Time (site submission to approval)	=local site REB approval date - local site submission date	90 days (average, if not using centralized process) 7 days (average, if the site is not a lead applicant and supplementary material submission is required)	Site	Quarterly
Local Site REB Approval to First Patient Recruited	=first patient recruited to the site - local site REB approval date	90 days (average)	Site	Quarterly
Site Open to Accrual to First Patient Recruited	=first patient recruited to the site - site open to accrual date	60 days (average)	Site	Quarterly
Recruiting Period (from open to closed to accrual)	= site closed to accrual date - site open to accrual date	300 days (average)	Site	Quarterly
Site Accrual vs. Site Target	= total accrual when closed/ site accrual set when the site open to accrual	Sites recruited to 60% of site target 40% of sites recruiting greater than 75% of site target	Site	Quarterly
SOPs	Sites to use regulatory compliant clinical trial operations standard operating procedures (SOPs)	100% of sites	Site	Annual
CTRNet	Number of sites who have registered with CTRNet	100% of sites	Site	Annual

Table 2: Study Impact Criteria Definitions

Impact Assessment	Impact Category	Proposed Definition
Trial categories of special interests	Novel Therapy	Trials involving newly developed intervention (e.g. drug, novel biomarker or diagnosis)
	Rare Cancer Setting	cancer that occurs in <6 out of 100,000 people each year
	Patient Management	Patient education, awareness, self- assessment trials, symptom control, improving patient experience
	Vulnerable Populations	Pediatric, AYA, elderly, organ dysfunction
	Lifestyle Interventions	Trials focused on lifestyle changes that may prevent, decrease severity and/or delay disease progression and treatment side effects (e.g. exercise, diet)
	Precision Medicine	Biomarker, immunotherapy, diagnosis, and targeted therapies
Potential Impact on Patient Population	Breakthrough Trial	Trial involving a first in class, or novel intervention (drug, biologic, technology or technique) that could dramatically change how people with a particular type of cancer are treated
	Platform Trial	Using already available (e.g. FDA approved) interventions for new combination, new types, settings or stages of cancer
	Enhancement/ Derivative Trial	Using additional targeting biomarker screening to tailor treatment and investigate outcomes (question should this also include imaging enhanced treatment)
	Sustaining Trial	Calibrating/focusing on dosages, treatment cycles or schedule (e.g. colon cancer adjuvant 3 - 6 months)
	Cross Cancer Trial	Results applied to multiple disease sites or basket/umbrella trials
Innovativeness of Trials	Incremental	Potential for iterative changes/advancement (e.g. next in class drugs)
	Paradigm Shifting	Potential for radical improvements in cancers/policy changes within cancer, or across a cancer spectrum (e.g. first in class drugs in phase III trials; introduction of new previously unused intervention or approach; first trials of OncotypeDx in local breast cancer that transformed patient management; first immunotherapy trials)
Study Results	Positive/Negative	Based on comparison of published results with the study primary outcome/end points

Table 3. Reporting Periods and Dates Q4 2014/15 – Q4 2019/20

Fiscal Year	Quarter	Period	Recruitment Database Lock
2014/15	Q3	October – December 2014	NA*
	Q4	January – March 2015	NA*
2015/16	Q1	April – June 2015	NA*
	Q2	July – September 2015	October 20, 2015
	Q3	October – December 2015	March 31, 2016
	Q4	January – March 2016	May 31, 2016
2016/17	Q1	April – June 2016	August 31, 2016
	Q2	July – September 2016	November 15, 2016
	Q3	October – December 2016	February 15, 2017
	Q4	January – March 2017	May 31, 2017
2017/18	Q1	April – June 2017	August 31, 2017
	Q2	July – September 2017	September 30, 2017
	Q3	October – December 2018	December 31, 2018
	Q4	January – March 2018	May 15, 2018
2018/19	Q1	April – June 2018	August 31, 2018
	Q2	July – September 2018	November 30, 2018
	Q3	October – December 2018	February 15, 2019
	Q4	January – March 2019	May 31, 2019
2019/20	Q1	April – June 2019	August 31, 2019
	Q2	July – September 2019	November 30, 2019
	Q3	October – December 2019	February 15, 2020
	Q4	January – March 2020	July 7, 2020

*Dates not available; database lock implemented in Q2 2015/16